Globus Medical Inc (NYSE: GMED)

Globus Medical, Inc., a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. It offers approximately 120 products that address an array of spinal pathologies, anatomies, and surgical approaches. The company’s fusion products are used in cervical, thoracolumbar, sacral, and interbody/corpectomy fusion procedures to treat degenerative, deformity, tumor, and trauma conditions. Its disruptive technology products provide material improvements to fusion procedures, such as minimally invasive surgical techniques, as well as new treatment alternatives, which include motion preservation technologies, such as dynamic stabilization, total disc replacement and interspinous process spacer products, and advanced biomaterials technologies; and interventional pain management solutions, including treatments for vertebral compression fractures.
Take a look at the 1-year chart of Globus (NYSE: GMED) below with added notations:

GMED has been trading sideways for the last 2 months, while forming a common pattern known as a rectangle. A minimum of (2) successful tests of the support and (2) successful tests of the resistance will give you the pattern. GMED’s rectangle pattern has formed a $20 resistance (red) and a $19 support (green). At some point the stock will have to break one way or the other.

The Tale of the Tape: GMED is trading within a rectangle pattern. The possible long positions on the stock would be either on a pullback to $19, or on a breakout above $20. Short opportunities would be on a rally up to $20, or on a break below $19.
Please share this article

5 Best Biotech Stocks to Buy Now

Biotech stocks to buy aren’t exactly the most popular investments on Wall Street right now.
The “risk on” environment of 2013 seems to have evaporated, with volatility heating up and many investors taking shelter in old stalwarts like consumer staples and even bond funds. Biotech stocks are often seen as risky and more speculative by investors, particularly those who prefer entrenched health care stocks like Johnson & Johnson (JNJ[2]) or Pfizer (PFE[3]) in Big Pharma.

But if you’re looking for outperformance in 2015, then the modest risk but big-time potential of biotech stocks could be just what the doctor ordered.
There are many reasons to be bullish on healthcare stocks broadly — both because of the recession-proof nature of the sector, and the growth that is sure to come from greater access to insurance via Obamacare and demographic tailwinds thanks to aging Boomers who will need more care and medications. (more)

Please share this article

Despite Struggle, Gold & Shares Coiled For Upside Explosion

from King World News
Today KWN is putting out a special piece which features an incredible chart showing that despite the recent weakness, gold and the gold shares may be coiled for a major upside explosion. These are charts that the big banks follow closely, as well as big money and savvy professionals. David P. out of Europe sent us the key chart that all KWN readers around the world need to see.
Below is the remarkable chart sent to KWN by David P. out of Europe, along with his brief commentary.
Epic Chart Reveals The Massive Opportunity In Gold Stocks
Continue Reading at KingWorldNews.com…
Please share this article

Homebuilder Update (Start Shorting Again)

investmentresearchdynamics.com / by David Kranzler / October 20, 2014
The homebuilder stocks had a steep sell-off that occurred the week of October 6.  It culminated a move lower that started the first of week of July when the Dow Jones Home Construction Index (DJUSHB) topped out at 520.  From that top to the low of 428 on October, the DJUSHB dropped 17.6%.   In that same time period, the S&P 500 dropped only 2%.  There’s a message there…


READ MORE

Please share this article

Is There Money To Be Made With Russian Stocks?

I see you’re interested in buying the dip in Russian stocks this morning.
But before you do, let me try to knock some sense into that skull of yours…
Late last week, I reminded you why we bid farewell to the big Russian bear back over the summer. At the time, Russia was one of the cheapest markets in the world. But cheap can always get even cheaper—and Russia is certainly no exception. With comic book supervillain Vlad Putin manning the controls from his secret Siberian lair, the Market Vectors Russia ETF (NYSE:RSX) has dropped a cold 20% since registering its late June highs.

So you’re still looking to take a shot at Russian stocks?
Why? Because of a rapidly-plummeting ruble? Or the chance that these beaten-down names just might be finished with their largest declines?  (more)

Please share this article